Tapcin

Tapcin is a dual inhibitor for topoisomerase I and topoisomerase II, with IC50 of 203 and 71 nM. Tapcin inhibits proliferations of cancer cells A-375, HeLa, Huh7.5, U2-OS, A549, Caco-2 and HT29, with IC50s of 441, 1.04, 40.5, 0.002, 0.006, 0.287 and 0.842 nM, respectively. Tapcin exhibits antitumor activity in HT29 xenograft model[1].

Product Specifications

UNSPSC

12352005

Target

Topoisomerase

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tapcin.html

Smiles

O=C([C@H](C)NC([C@H](C)NC(CC(O)CCCCCCCCCCC)=O)=O)NC1=CC=C(C2=NC(C3=NC(C4=NC(C(N[C@H](C(NC5=CC=C(C(NC6=C(OC(C)C)C(O)=C(C(NC7=CC=C(C(O)=O)C=C7)=O)C=C6)=O)C=C5)=O)CC(N)=O)=O)=CS4)=CS3)=CS2)C=C1

Molecular Formula

C64H73N11O13S3

Molecular Weight

1300.53

References & Citations

[1]Wang Z, et al., Tapcin, an In Vivo Active Dual Topoisomerase I/II Inhibitor Discovered by Synthetic Bioinformatic Natural Product (Syn-BNP) -Coupled Metagenomics. Angew Chem Int Ed Engl. 2024 Apr 22;63 (17) :e202317187.